News Releases
- September 29, 2022Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference
- September 13, 2022Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
- September 8, 2022Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders
- August 29, 2022Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
- August 24, 2022Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
- August 8, 2022Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
- August 1, 2022Annovis Bio to Participate on Alzheimer's Association International Conference Panel
- July 14, 2022Annovis Bio to Present at the Alzheimer's Association International Conference
- July 7, 2022Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
- June 9, 2022Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top